The Full Federal Court has overturned a win for the consumer regulator in a case against Sydney-based Unique International College, ruling that the vocational trainer’s practices for marketing and enrolling students in its diploma courses did not amount to unconscionable conduct.
A judge has agreed to sign off on an order in a massive class action against Westpac that could give 25 percent of any recovery to the litigation funder underwriting the case, on the condition that the funder accept a rate reflecting the net, not the gross, sum.
Bega has admitted to allegations by Kraft that it distributed its peanut butter in boxes with the Kraft logo on the outside, but says it was allowed to under a license agreement.
The deputy chairman of the Australian Securities and Investments Commission, Peter Kell, has resigned just five months into a yearlong extension of his contract with the corporate watchdog.
MyBudget has successfully fought off a class action brought by consumers who claimed the budget management firm violated consumer law by holding onto interest earned on their personal budgeting accounts.
Generic drug company Alphapharm has lost a bid for documents it claimed would show Sanofi-Aventis suspected as early as 2015 that patents for one of its injector pens may be invalid.
Australia needs stronger regulation to prevent the country’s major airports from abusing their market power, the Australian Competition and Consumer Commission said Tuesday.
Hytera Communications has until Thursday to reveal what evidence has been or will be withheld from Motorola in their intellectually property battle in compliance with strict Chinese state security and cybersecurity laws.
A judge has said a case filed by Hyundai Engineering & Steel Industries to enforce a $7.9 million arbitration award against Alfasi Steel over the delayed construction of Sydney’s International Conference Centre can move forward even though Alfasi has gone into administration.
Generic drug maker Dr Reddy’s Laboratories has reached a settlement with US-based Millennium Pharmaceuticals, agreeing to be restrained from selling a cheap version of cancer drug Velcade in Australia.
For information on rights and reprints, contact subscriptions@lawyerly.com.au
